Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction

被引：0
作者：
J D Brioni
M Nakane
G C Hsieh
R B Moreland
T Kolasa
J P Sullivan
机构：
[1] Neuroscience Research,
[2] Global Pharmaceutical Research and Development,undefined
[3] Abbott Laboratories,undefined
来源：
International Journal of Impotence Research | 2002年 / 14卷
关键词：
guanylate cyclase; YC-1; penile erection; erectile dysfunction; corpus cavernosum; sildenafil; cGMP;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Soluble guanylate cyclase (sGC) is an important enzyme in corpus cavernosum smooth muscle cells as it is one of the regulators of the synthesis of cGMP. The efficacy of sildenafil (Viagra™) in the treatment of male erectile dysfunction indicates the importance of the cGMP system in the erectile response as the increased levels of cGMP induce relaxation of the corpus cavernosum. sGC is physiologically activated by nitric oxide (NO) during sexual stimulation, and its activity can be pharmacologically enhanced by several NO-donors. Agents like YC-1 can also activate sGC after binding to a novel allosteric site in the enzyme, a site different from the NO binding site. YC-1 can relax rabbit cavernosal tissue and it facilitates penile erection in vivo. This review summarizes the enzymology, biochemistry and pharmacology of this novel allosteric site and its relevance for the regulation of penile function. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they could be beneficial for the treatment of male erectile dysfunction.
引用
收藏
页码：8 / 14
页数：6
相关论文
共 114 条
  • [11] Azam M(1986)Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 261 7236-350.
  • [12] Yang L(1999)Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1411 334-278.
  • [13] Danziger RS(1990)Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. Eur J Biochem 190 273-5.
  • [14] Harteneck Cetal(1996)Characterization of 1H-[1,2,4]oxadi-azolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50 1-309.
  • [15] Giuili G(1998)Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol 123 299-156.
  • [16] Scholl U(1981)Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol 59 150-288.
  • [17] Bulle F(1988)LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther 247 283-374.
  • [18] Guellaen G(1993)Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 45 367-109.
  • [19] Zabel U(1999)LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels. Eur J Pharmacol 366 101-1594.
  • [20] Weeger M(1995)Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta. Br J Pharmacol 114 1587-91.
12345678910